PPARγ activation serves as therapeutic strategy against bladder cancer via inhibiting PI3K-Akt signaling pathway

PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy

(2018) Kenneth K.W. To et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib

(2017) Jayaprakash D. Karkera et al.   MOLECULAR CANCER THERAPEUTICS

Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer

(2017) Manav Korpal et al.   Nature Communications

Rosiglitazone increases endothelial cell migration and vascular permeability through Akt phosphorylation

(2017) Yun Hyi Ku et al.   BMC Pharmacology & Toxicology

Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes

(2016) E. Erdmann et al.   DIABETES OBESITY & METABOLISM

Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

(2016) Theo Vos et al.   LANCET

FOXA1, GATA3 and PPARɣ Cooperate to Drive Luminal Subtype in Bladder Cancer: A Molecular Analysis of Established Human Cell Lines

(2016) Joshua I. Warrick et al.   Scientific Reports

Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes

(2015) James D. Lewis et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy

(2014) Woonyoung Choi et al.   CANCER CELL

The PPARγ agonist Troglitazone induces autophagy, apoptosis and necroptosis in bladder cancer cells

(2014) S Yan et al.   CANCER GENE THERAPY

Comprehensive molecular characterization of urothelial bladder carcinoma

(2014)   NATURE

Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer

(2014) Woonyoung Choi et al.   Nature Reviews Urology

Independent Component Analysis Uncovers the Landscape of the Bladder Tumor Transcriptome and Reveals Insights into Luminal and Basal Subtypes

(2014) Anne Biton et al.   Cell Reports

Small Molecule Agonists of PPAR-γ Exert Therapeutic Effects in Esophageal Cancer

(2013) Hiroshi Sawayama et al.   CANCER RESEARCH

International Variations in Bladder Cancer Incidence and Mortality

(2013) Saurabh Chavan et al.   EUROPEAN UROLOGY

Pan-cancer patterns of somatic copy number alteration

(2013) Travis I Zack et al.   NATURE GENETICS

Effects of PPARγ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells

(2012) Marianna Terrasi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

The Role of Peroxisome Proliferator-Activated Receptors in the Esophageal, Gastric, and Colorectal Cancer

(2012) Alessandra Fucci et al.   PPAR Research

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

The Antidiabetic Drug Ciglitazone Induces High Grade Bladder Cancer Cells Apoptosis through the Up-Regulation of TRAIL

(2011) Marie-Laure Plissonnier et al.   PLoS One

Insights on distinct pathways of thiazolidinediones (PPARγ ligand)-promoted apoptosis in TRAIL-sensitive or -resistant malignant urothelial cells

(2010) Marie Laure Plissonnier et al.   INTERNATIONAL JOURNAL OF CANCER

β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation

(2010) I Ahmad et al.   ONCOGENE

Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer

(2009) F. M. Platt et al.   CLINICAL CANCER RESEARCH

Tenets of PTEN Tumor Suppression

(2008) Leonardo Salmena et al.   CELL